LXR/CD38 activation drives cholesterol-induced macrophage senescence and neurodegeneration via NAD + depletion.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro and animal mechanism study with no human clinical data
PubMed 38636518 · doi:10.1016/j.celrep.2024.114102
What was done
The authors investigated the molecular mechanisms linking dysregulated cholesterol metabolism and cellular aging in age-related macular degeneration (AMD). They evaluated the pathway involving liver X nuclear receptor (LXR) activation, CD38 upregulation, lysosomal cholesterol efflux, and nicotinamide adenine dinucleotide (NAD+) depletion in macrophages under metabolic and genotoxic stress. They also tested the effects of NAD+ augmentation, genetic and pharmacological senolysis, and subretinal administration of healthy macrophages in preclinical models.
What was found
Metabolic and genotoxic stresses acted through LXR to upregulate CD38 and promote lysosomal cholesterol efflux, leading to intracellular NAD+ depletion in macrophages. This cholesterol-mediated NAD+ deficit triggered macrophage senescence and promoted AMD features including subretinal lipid deposition and neurodegeneration. NAD+ augmentation reversed senescence and macrophage dysfunction, preventing the AMD phenotype. Genetic and pharmacological senolysis protected against AMD progression and neurodegeneration, and subretinal healthy macrophage delivery promoted senescent cell clearance and reduced disease burden. The abstract does not provide specific numerical values, effect sizes, or confidence intervals.
Why it matters
The study delineates a mechanistic link between intracellular cholesterol accumulation, CD38-mediated NAD+ depletion, macrophage senescence, and retinal neurodegeneration. These findings identify NAD+ replenishment, senolytic approaches, and macrophage-targeted interventions as potential therapeutic strategies for AMD.
Limits
The abstract does not report numerical data, exact sample sizes, or specific animal/cell model counts. Because findings are derived from preclinical laboratory models, safety, clinical efficacy, and direct translation to human AMD remain unverified.
Cited by
- supports Chronic immune activation results in a deficiency of intracellular NAD within immune cells.